Yeast-derived Glycoprotein B-1 of Herpes Simplex Virus (HSV) as a Candidate for an HSV Vaccine
Although antiherpes drugs such as acyclovir or Ara-A are available, herpes simplex virus (HSV) infections are still a serious clinical problem. Under the circumstances, as a method of prophylaxis, vaccine development seems to be very important. As candidates for HSV vaccines, deletion-mutant live attenuated vaccines (1) and subunit vaccines consisting of viral glycoproteins (2, 3) have been extensively investigated.
KeywordsHerpes Simplex Virus Rhesus Monkey Trigeminal Ganglion Subunit Vaccine Recurrent Lesion
Unable to display preview. Download preview PDF.
- 10.Burke, R. L., Van Nest, G., Carlson, J., Gervase, B., Goldbeck, C., Ng, P., Sanchez-Pescador, L., Stanberry, L. R. and Ott, G. (1989) in Vaccines 89 ( Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. ), pp. 377–382.Google Scholar
- 11.Meignier, B., Jourdier, T. M., Norrild, B., Pereira, L. and Roizman, B. (1987) J. Infect. Dis. 155921–930.Google Scholar